Wegovy Health Risks: What the Evidence Actually Shows

Step 1: Recognise the common semaglutide health risks, and why most are front-loaded

The NHS medicines page for semaglutide lists the most common unwanted effects as nausea, vomiting, diarrhoea, constipation, indigestion, reflux, and burping. Fatigue, headache, dizziness, and injection-site reactions also appear in the data. None of that makes comfortable reading on paper, but the clinical picture is more nuanced: these effects cluster around the time you start treatment and in the days after each dose step up. Your body is adjusting to slower gastric emptying and reduced appetite signalling; for most people the discomfort is self-limiting.

Eating smaller portions, cutting fatty foods while your system adjusts, and staying well hydrated all help. Our prescribers hear this question most weeks: "Will the nausea last the whole time?" The honest answer from the trial data is that it usually does not, though a small number of people find the GI effects persistent enough to reconsider the dose or the medicine altogether. That is a clinical conversation, not a guess. You can read a more detailed breakdown of Wegovy's side effects alongside the management strategies patients find useful.

Dehydration is worth flagging separately. If vomiting or diarrhoea is severe enough to stop you keeping fluids down, there is a knock-on risk to kidney function. Sip water steadily, and contact a clinician if you cannot maintain fluid intake.

Step 2: Know the less common risks that carry more clinical weight

Beyond the GI-led profile, the semaglutide health risks that warrant closer attention fall into a few categories.

Pancreatitis. On 29 January 2026 the MHRA published a Drug Safety Update confirming that acute pancreatitis is a known, infrequent but serious side effect of GLP-1 medicines. The signal is severe, persistent abdominal pain (often radiating to the back) with or without vomiting. If that happens, stop the injection and get urgent medical assessment. Do not assume it is ordinary indigestion. You can report suspected side effects through the MHRA Yellow Card scheme, which is open to patients as well as healthcare professionals.

Gallbladder problems. Rapid weight loss of any kind increases the risk of gallstones. Pain in the upper right abdomen, especially after eating, should be assessed by a doctor.

Heart rate. A small increase in resting heart rate has been observed in trials. It is rarely clinically significant, but worth noting if you already have a cardiac condition.

Allergic reactions. Rash, swelling or breathing difficulty after an injection requires emergency attention. The wider risks and side-effect profile of Wegovy covers these scenarios in more detail.

Mental health. Some people on GLP-1 medicines have reported low mood or, in rare cases, thoughts of self-harm. The MHRA continues to monitor this signal. If your mood changes noticeably during treatment, raise it with your prescribing team. There is dedicated information on the mental health side effects of Wegovy if you want to explore that area further.

Step 3: Understand who the risks are highest for, and when Wegovy should not be used

Wegovy's UK licence does not extend to everyone who might want to use it. The risks are categorically unacceptable in certain groups, and a responsible prescriber will screen for them before issuing a prescription. People who are pregnant, trying to conceive, or breastfeeding should not use semaglutide; animal studies raised embryotoxicity concerns and there is no adequate human safety data in these situations. Anyone under 18 is also outside the licensed indication.

A personal or close family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 is a contraindication. A history of pancreatitis or certain inflammatory bowel conditions warrants detailed prescriber discussion rather than a straightforward go-ahead.

The risks of taking Wegovy in specific health situations goes into more depth on co-existing conditions. For a broader view of how Wegovy fits into a clinical plan, the Wegovy overview page covers the full picture of how the medicine is used in UK practice.

Lower BMI thresholds can apply for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, eligibility is not one-size-fits-all, and the prescriber considers the whole picture, not just one number. You can explore weight-loss treatment options more broadly to see where Wegovy sits alongside other licensed medicines.

When to get medical help

Call 999 or go to A&E immediately for: a severe allergic reaction (swelling of the face, throat or tongue, difficulty breathing); chest pain or palpitations that feel out of the ordinary; severe persistent abdominal pain with or without vomiting.

Contact your prescribing team or GP promptly for: nausea, vomiting or diarrhoea lasting more than two or three days; signs of dehydration (very dark urine, confusion, dizziness on standing); upper abdominal or right-side pain after eating; any change in mood, low spirits or intrusive thoughts. The newer Wegovy side-effect findings summarise what has emerged from post-marketing surveillance since the medicine's approval. If anything feels uncertain, our prescribers are reachable through our support team seven days a week.

Knowing what normal adjustment looks like (and what falls outside it) is one of the most useful things you can carry into treatment. If you are weighing whether semaglutide is right for you given your health history, a free consultation with a GPhC-registered prescriber at nume is the next practical step. Check your eligibility and have that conversation with someone qualified to give you a personal answer.